Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Advance Auto Parts, Inc. (AAP) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance

Advance Auto Parts, Inc.Trade
Amylx Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Advance Auto Parts, Inc. vs Amylx Pharmaceuticals Inc — how do they compare? Advance Auto Parts, Inc. trades at $53.12 (market cap $3.19B), while Amylx Pharmaceuticals Inc trades at $24.03 (market cap $2.64B). The key difference: Advance Auto Parts, Inc. is the larger of the two by market cap, and Advance Auto Parts, Inc. pays a 1.89% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AAPAMLX
Market Cap
$3.19B$2.64B
Sector
Consumer CyclicalHealth
52-Week High
$64.17$24.19
52-Week Low
$38.75$7.82
Enterprise Value
$5.47B$2.39B
Dividend Yield
1.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Advance Auto Parts, Inc.

Advance Auto Parts (AAP) trades at $55.73, down 3.58% today, reflecting bearish technical signals amid mixed fundamentals. The company reported Q1 2026 EPS of $0.77, beating expectations, with revenue at $8.6 billion for 2025 but a slim net income margin of 0.51%. Recent news highlights restructuring efforts and AI-driven delivery initiatives to stabilize operations.

The outlook is cautious; while valuation ratios like P/S of 0.37 appear attractive, weak profitability and negative operating cash flow pose risks. Analyst consensus is mixed with a $61.30 price target, but high debt and competitive pressures require monitoring for sustained turnaround progress.

Amylx Pharmaceuticals Inc

AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.

Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.

Returns comparison

Trailing returns across standard periods

About Advance Auto Parts, Inc.

Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.

Read more on AAP

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX